KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Bausch Health Companies (BHC) Interest Expenses (2016 - 2026)

Bausch Health Companies' Interest Expenses history spans 18 years, with the latest figure at $402.0 million for Q1 2026.

  • On a quarterly basis, Interest Expenses rose 21.82% to $402.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $1.7 billion, a 22.96% increase, with the full-year FY2025 number at $1.6 billion, up 15.56% from a year prior.
  • Interest Expenses hit $402.0 million in Q1 2026 for Bausch Health Companies, up from $397.0 million in the prior quarter.
  • Over the last five years, Interest Expenses for BHC hit a ceiling of $465.0 million in Q2 2025 and a floor of $307.0 million in Q4 2022.
  • Historically, Interest Expenses has averaged $363.9 million across 5 years, with a median of $355.0 million in 2024.
  • Biggest five-year swings in Interest Expenses: dropped 22.2% in 2023 and later surged 32.86% in 2025.
  • Tracing BHC's Interest Expenses over 5 years: stood at $307.0 million in 2022, then grew by 18.24% to $363.0 million in 2023, then dropped by 7.16% to $337.0 million in 2024, then grew by 17.8% to $397.0 million in 2025, then rose by 1.26% to $402.0 million in 2026.
  • Business Quant data shows Interest Expenses for BHC at $402.0 million in Q1 2026, $397.0 million in Q4 2025, and $412.0 million in Q3 2025.